Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daniel Chancellor

Latest From Daniel Chancellor

Is CAR-NK The Natural Successor To CAR-Ts?

There is significant commercial potential on offer for the leading CAR-NK developers. While companies committed to continued CAR-T development will need to adapt and innovate in order to remain relevant, especially considering this disruptive new drug class.

Clinical Trials Innovation

The Tumor-Agnostic Developer’s Toolkit

In Vivo has identified the pipeline of next-generation tumor-agnostic drugs and created a guide to the ideal trial strategies for these potentially transformative candidates.

Commercial Innovation

In Vivo's Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.

Business Strategies Companies

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

Business Strategies Companies

Opening The Door For Cell Therapy In Solid Tumors

The next frontier for cell therapy is solid tumors – and of the many attempts to move from liquid to solid tumors, tumor infiltrating lymphocytes and other CAR-T constructs are some of the most promising. 

Clinical Trials ImmunoOncology

PharmAI – Industry Is Smartening Up To Potential Of Artificial Intelligence

AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.

Artificial Intelligence Business Strategies
See All
UsernamePublicRestriction

Register